Screening for patients at risk for cardiac amyloidosis via electronic health records: A multicenter machine learning development and validation study

Timely detection is crucial to improve outcomes in patients with cardiac amyloidosis (CA) by initiation of guideline-directed disease-modifying treatments. Although confirmatory bone scintigraphy is highly accurate for CA detection, identifying at-risk patients for referral remains challenging. This study aimed to develop and validate a machine learning model, Amylo-Detect , using structured multimodal electronic health record (EHR) data to guide referrals for confirmatory scintigraphy and monoclonal protein testing. Consecutive all-comer patients (n = 11,616) referred for bone scintigraphy at the Vienna General Hospital (2010–2023) were retrospectively included. Patients referred before August 2020 formed the development cohort. The remaining patients comprised the internal validation cohort. External validation was performed at the University Hospital Essen (n = 1,521). Amylo-Detect was trained using 50 routinely available parameters to predict CA-suggestive uptake (Perugini grade ≥2) and compared with an existing score and clinical routine. High-grade uptake was present in 388 patients (3.0%). Amylo-Detect demonstrated excellent performance in development (AUC 0.93), independent internal validation (AUC 0.91), and external validation cohort (AUC 0.91), outperforming existing scoring systems and clinical routine. Results were consistent across subgroups, even when crucial predictors were missing. Of the 42/388 (10.8%) patients missed in clinical routine, 12/42 (29%) were additionally detected by Amylo-Detect . The model further conveyed significant prognostic value for mortality and heart failure hospitalization. We present Amylo-Detect , a validated EHR-based tool for CA risk prediction, available as a web app, allowing application and further evaluation. By improving timely detection and referral, Amylo-Detect may help address diagnostic delays, pending prospective evaluation.

Authors

Institutions

Publication Details

Journal
PLOS Digital Health
Published
2026-10-08
DOI
https://doi.org/10.1371/journal.pdig.0001637
Primary Topic
Amyloidosis: Diagnosis, Treatment, Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Screening for patients at risk for cardiac amyloidosis via electronic health records: A multicenter machine learning development and validation study

Christian Hengstenberg, Clemens P. Spielvogel, Ken Herrmann, Julia Mascherbauer et al.
PLOS Digital Health
Amyloidosis: Diagnosis, Treatment, Outcomes
article

Screening for patients at risk for cardiac amyloidosis via electronic health records: A multicenter machine learning development and validation study

Christian Hengstenberg, Clemens P. Spielvogel, Ken Herrmann, Julia Mascherbauer, Josef Yu, Philipp Emanuel Bartko, Stephan Settelmeier, Tatjana Traub‐Weidinger, Jens Kleesiek, Felix Hofer, Raffaella Calabretta, Christian Nitsche, Kilian Kluge, Gregor J. Kasprian, David Kersting, Tienush Rassaf, Laurenz Hauptmann, Katharina Mascherbauer, Juliane Hennenberg, Markus Kofler, Andreas Anselm Kammerlander, Jing Ning, Katarina Kumpf, David Haberl, Marcus Hacker, Kim Moon, Maximilian Autherith
article en

Abstract

Timely detection is crucial to improve outcomes in patients with cardiac amyloidosis (CA) by initiation of guideline-directed disease-modifying treatments. Although confirmatory bone scintigraphy is highly accurate for CA detection, identifying at-risk patients for referral remains challenging. This study aimed to develop and validate a machine learning model, Amylo-Detect , using structured multimodal electronic health record (EHR) data to guide referrals for confirmatory scintigraphy and monoclonal protein testing. Consecutive all-comer patients (n = 11,616) referred for bone scintigraphy at the Vienna General Hospital (2010–2023) were retrospectively included. Patients referred before August 2020 formed the development cohort. The remaining patients comprised the internal validation cohort. External validation was performed at the University Hospital Essen (n = 1,521). Amylo-Detect was trained using 50 routinely available parameters to predict CA-suggestive uptake (Perugini grade ≥2) and compared with an existing score and clinical routine. High-grade uptake was present in 388 patients (3.0%). Amylo-Detect demonstrated excellent performance in development (AUC 0.93), independent internal validation (AUC 0.91), and external validation cohort (AUC 0.91), outperforming existing scoring systems and clinical routine. Results were consistent across subgroups, even when crucial predictors were missing. Of the 42/388 (10.8%) patients missed in clinical routine, 12/42 (29%) were additionally detected by Amylo-Detect . The model further conveyed significant prognostic value for mortality and heart failure hospitalization. We present Amylo-Detect , a validated EHR-based tool for CA risk prediction, available as a web app, allowing application and further evaluation. By improving timely detection and referral, Amylo-Detect may help address diagnostic delays, pending prospective evaluation.

PLOS Digital HealthVol. 5(10)
Austrian Research Institute for Artificial Intelligence (AT), Donauspital (AT), Universitätsklinikum St. Pölten (AT), Essen University Hospital (DE), West German Heart and Vascular Center Essen (DE), Artificial Intelligence in Medicine (Canada) (CA), University of Duisburg-Essen (DE), Medical University of Vienna (AT)
Openalex Percentile: Top 22%
Amyloidosis: Diagnosis, Treatment, Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.